GlassScriptPhysician profile
Christopher Matthew Jenkins
NPI 1497284699
$14,866.02
in general payments reported to CMS, 2019-2025
36 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $671 · 2021: $3,418 · 2022: $4,733 · 2023: $3,790 · 2024: $903 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,167 · Travel and Lodging: $602 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,167.33 |
| Travel and Lodging | $602.00 |
| Education | $164.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $3,341.76 | 2021-2023 | Acticor 7 Vr-T Dx |
| Penumbra, INC. | $2,432.77 | 2022-2023 | Indigo System |
| Medtronic, INC. | $1,036.17 | 2021-2024 | Onyx Frontier, Corevalve Evolut R, Ffrangio |
| Boston Scientific Corporation | $903.78 | 2022-2025 | Avvigo Guidance System, Watchman Flx, Ffr Link Bluetooth Communication Module |
| Abbott Laboratories | $882.46 | 2021-2025 | Supera, Emboshield Nav6, Perclose Prostyle |
| Janssen Pharmaceuticals, INC | $824.38 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $776.90 | 2020-2025 | Lifevest |
| Abiomed | $713.03 | 2022-2025 | Impella |
| Shockwave Medical, INC | $654.24 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Pfizer INC. | $404.91 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $294.37 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $289.09 | 2021-2024 | |
| Novo Nordisk INC | $269.83 | 2021-2025 | Wegovy |
| Inari Medical, INC. | $254.86 | 2020-2021 | |
| Amgen INC. | $241.96 | 2021-2023 | Repatha |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $240.29 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $213.96 | 2021 | |
| Philips North America LLC | $201.86 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Janssen Scientific Affairs, LLC | $113.17 | 2020 | |
| Stryker Corporation | $109.64 | 2025 | Flowtriever, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Teleflex LLC | $106.00 | 2025 | Turnpike |
| Janssen Biotech, INC. | $99.69 | 2022 | |
| Kestra Medical Technology Services, INC. | $89.65 | 2022-2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $72.62 | 2022-2025 | Opsynvi |
| Angiodynamics, INC. | $49.84 | 2025 | Alphavac |
| Baxter Healthcare | $38.39 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Cardiva Medical, INC. | $34.13 | 2025 | Cardiva Vascade 6/7f Vcs |
| Lemaitre Vascular, INC. | $34.10 | 2025 | Artegraft Vascular Graft |
| Astrazeneca Pharmaceuticals LP | $32.38 | 2022-2023 | Andexxa |
| Livanova USA, INC. | $22.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.82 | 2022 | |
| Biosense Webster, INC. | $20.09 | 2022 | |
| Merck Sharp & Dohme LLC | $16.48 | 2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $13.80 | 2021 | |
| Abbvie INC. | $12.50 | 2020 | |
| Cardiovascular Systems INC. | $3.04 | 2023 | Diamondback Coronary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.